|
|
Blood, 15 December 2004, Vol. 104, No. 13, pp. 4300-4307.
Prepublished online as a Blood First Edition Paper on August 24, 2004; DOI 10.1182/blood-2004-04-1631.
 Previous Article | Table of Contents | Next Article 
RED CELLS
Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease
Yoko Nakano,
Shigehiko Imagawa,
Ken Matsumoto,
Christian Stockmann,
Naoshi Obara,
Norio Suzuki,
Takeshi Doi,
Tatsuhiko Kodama,
Satoru Takahashi,
Toshiro Nagasawa, and
Masayuki Yamamoto
From the Division of Hematology, Institute of Clinical Medicine, the Center for Tsukuba Advanced Research Alliance and the Division of Anatomy and Embryology, Institute of Basic Medical Sciences, University of Tsukuba, Japan; the Institute für Physiologie, Universitätsklinikum Essen, Germany; the Tokyo New Drug Research Laboratories, Kowa Co, Ltd, and the Laboratory for Systems Biology and Medicine Research Center for Advanced Science and Technology, University of Tokyo, Japan.
Erythropoietin (Epo) gene expression is under the control of hypoxia-inducible factor 1 (HIF-1), and is negatively regulated by GATA. Interleukin 1 (IL-1) and tumor necrosis factor  (TNF-), which increase the binding activity of GATA and inhibit Epo promoter activity, are increased in patients with anemia of chronic disease (ACD). We previously demonstrated the ability of K-7174 (a GATA-specific inhibitor), when injected intraperitoneally, to improve Epo production that had been inhibited by IL-1 or TNF- treatment. In the present study, we examined the ability of both K-11706, which inhibits GATA and enhances HIF-1 binding activity, and K-13144, which has no effect on GATA or HIF-1 binding activity, to improve Epo production following inhibition by IL-1 or TNF- in Hep3B cells in vitro and in an in vivo mouse assay. Oral administration of K-11706 reversed the decreases in hemoglobin and serum Epo concentrations, reticulocyte counts, and numbers of erythroid colony-forming units (CFU-Es) induced by IL-1 or TNF-. These results raise the possibility of using orally administered K-11706 for treating patients with ACD.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
I. C. Macdougall
Novel Erythropoiesis-Stimulating Agents: A New Era in Anemia Management
Clin. J. Am. Soc. Nephrol.,
January 1, 2008;
3(1):
200 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Hsieh, N. S. Linde, A. Wynter, M. Metzger, C. Wong, I. Langsetmo, A. Lin, R. Smith, G. P. Rodgers, R. E. Donahue, et al.
HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques
Blood,
September 15, 2007;
110(6):
2140 - 2147.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Inoue, M. Kobayashi, K. Yano, M. Miura, A. Izumi, C. Mataki, T. Doi, T. Hamakubo, P. C. Reid, D. A. Hume, et al.
Histone Deacetylase Inhibitor Reduces Monocyte Adhesion to Endothelium Through the Suppression of Vascular Cell Adhesion Molecule-1 Expression
Arterioscler. Thromb. Vasc. Biol.,
December 1, 2006;
26(12):
2652 - 2659.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
